EXTENDED REPORT
European League Against Rheumatism (EULAR)
recommendations for the management of psoriatic
arthritis with pharmacological therapies:
2015 update
L Gossec,
1,2
J S Smolen,
3,4
S Ramiro,
5
M de Wit,
6
M Cutolo,
7
M Dougados,
8,9
P Emery,
10,11
R Landewé,
12,13
S Oliver,
14
D Aletaha,
3
N Betteridge,
6
J Braun,
15
G Burmester,
16
J D Cañete,
17
N Damjanov,
18
O FitzGerald,
19
E Haglund,
20,21
P Helliwell,
22
T K Kvien,
23
R Lories,
24,25
T Luger,
26
M Maccarone,
27
H Marzo-Ortega,
10,11
D McGonagle,
10,11
I B McInnes,
28
I Olivieri,
29
K Pavelka,
30
G Schett,
31
J Sieper,
32
F van den Bosch,
33
D J Veale,
34
J Wollenhaupt,
35
A Zink,
36
D van der Heijde
5
For numbered affiliations see
end of article.
Correspondence to
Professor Laure Gossec, Hôpital
Pitié-Salpétrière, Service de
Rhumatologie, 47-83,
boulevard de l’Hôpital,
Paris 75013, France;
laure.gossec@aphp.fr
LG and JSS contributed
equally.
Received 30 July 2015
Revised 7 October 2015
Accepted 30 October 2015
To cite:Gossec L,
Smolen JS, Ramiro S,et al.
Ann Rheum DisPublished
Online First: [please include
Day Month Year] doi:10.1136/annrheumdis- 2015-208337
ABSTRACT
BackgroundSince the publication of the European
League Against Rheumatism recommendations for the
pharmacological treatment of psoriatic arthritis (PsA) in
2012, new evidence and new therapeutic agents have
emerged. The objective was to update these
recommendations.
MethodsA systematic literature review was performed
regarding pharmacological treatment in PsA.
Subsequently, recommendations were formulated based
on the evidence and the expert opinion of the 34 Task
Force members. Levels of evidence and strengths of
recommendations were allocated.
ResultsThe updated recommendations comprise
5 overarching principles and 10 recommendations,
covering pharmacological therapies for PsA from
non-steroidal anti-inflammatory drugs (NSAIDs), to
conventional synthetic (csDMARD) and biological
(bDMARD) disease-modifying antirheumatic drugs,
whatever t
【骨科-指南】2015+EULAR推荐：银屑病关节炎的药物治疗（更新版）.pdf